Ontology highlight
ABSTRACT: Introduction
LC350189 is a novel selective xanthine oxidase inhibitor under clinical development for the management of hyperuricemia in gout patients. The aim of this study was to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of the drug in healthy subjects.Methods
A dose-block randomized, double-blind, active and placebo-controlled, single- and multiple-dosing study was conducted. A single ascending dose (SAD) study (10-600 mg) and a multiple ascending dose (MAD) study with once-daily doses (100-800 mg) for 7 days were conducted. Serial samples of blood and urine for pharmacokinetics/pharmacodynamics analysis were collected, and tolerability and adverse events were assessed throughout the study.Results
Sixty-seven and 58 subjects were enrolled i
SUBMITTER: Yoon S
PROVIDER: S-EPMC4560520 | biostudies-literature | 2015
REPOSITORIES: biostudies-literature